FindTrial
Sign In

ENMD-2076

DRUG8 trials

Sponsors

CASI Pharmaceuticals, Inc., University Health Network, Toronto

Conditions

AdvancedAdvanced Adult Hepatocellular CarcinomaAdvanced CancerAdvanced Fibrolamellar CarcinomaFallopian CancerMetastaticMultiple MyelomaOvarian Cancer

Phase 1

A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer
CompletedNCT00658671
CASI Pharmaceuticals, Inc.Advanced Cancer
Start: 2008-04-30End: 2012-06-30Updated: 2023-02-06
Study of ENMD-2076 in Patients With Multiple Myeloma
CompletedNCT00806065
CASI Pharmaceuticals, Inc.Multiple Myeloma
Start: 2008-12-31End: 2012-01-31Updated: 2023-02-06
Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies
CompletedNCT00904787
CASI Pharmaceuticals, Inc.Relapsed or Refractory Hematological Malignancies
Start: 2009-04-30End: 2011-05-31Updated: 2011-08-04

Phase 2

Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
CompletedNCT01104675
CASI Pharmaceuticals, Inc.Fallopian Cancer, Ovarian Cancer, Peritoneal Cancer
Start: 2010-04-30End: 2012-12-31Updated: 2014-08-06
Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC
CompletedNCT01639248
CASI Pharmaceuticals, Inc.Triple Negative Breast Cancer
Start: 2012-07-31End: 2017-06-30Updated: 2017-06-26
Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma
CompletedNCT01719744
University Health Network, TorontoAdvanced, Metastatic, Soft Tissue Sarcoma
Start: 2013-01-31End: 2016-01-31Updated: 2023-08-01
A Study of ENMD-2076 in Ovarian Clear Cell Cancers
CompletedNCT01914510
University Health Network, TorontoOvarian Clear Cell Carcinoma
Start: 2013-09-30End: 2017-01-31Updated: 2019-12-13
A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
CompletedNCT02234986
CASI Pharmaceuticals, Inc.Advanced Adult Hepatocellular Carcinoma, Advanced Fibrolamellar Carcinoma
Start: 2015-10-31End: 2018-06-30Updated: 2025-04-18

Related Papers

Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies.
2022-04-12102 citations
A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer
Breast Cancer Research2018-08-0268 citations
Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret phase II consortium.
Journal of Clinical Oncology2017-05-206 citations
Antitumor activity, safety and predictive biomarker results of ENMD-2076 administered to patients (pts) with recurrent ovarian clear cell carcinoma (OCCC): A trial of the Princess Margaret Phase II Consortium.
Journal of Clinical Oncology2016-05-201 citations
Phase II study of oral ENMD-2076 administered to patients with ovarian clear cell carcinoma: A trial of the Princess Margaret Phase II Consortium.
Journal of Clinical Oncology2014-05-202 citations
Phase II study of oral ENMD-2076 administered to patients (pts) with advanced soft tissue sarcoma (STS).
Journal of Clinical Oncology2014-05-201 citations